DHR

Healthcare

Danaher Corporation

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2007–2025(19yr)

Revenue

Net Income

Free CF

Metric	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$11.0B	$12.7B	$11.2B	$13.2B	$16.1B	$18.3B	$19.1B	$19.9B	$20.6B	$16.9B	$18.3B	$19.9B	$17.9B	$22.3B	$29.5B	$31.5B	$23.9B	$23.9B	$24.6B	+2.9%
Gross Profit	$5.0B	$5.9B	$5.3B	$6.6B	$8.2B	$9.4B	$10.0B	$10.4B	$10.8B	$9.3B	$10.2B	$11.1B	$10.0B	$12.5B	$18.0B	$18.9B	$14.0B	$14.2B	$14.5B	+2.2%
Gross Margin	45.7%	46.8%	47.2%	50.2%	50.8%	51.6%	52.1%	52.4%	52.3%	55.3%	55.6%	55.8%	55.7%	56.0%	61.0%	60.2%	58.7%	59.5%	59.1%	-0.4pp
Operating Income	$1.7B	$1.9B	$1.5B	$2.2B	$2.6B	$3.2B	$3.3B	$3.4B	$3.5B	$2.8B	$3.0B	$3.4B	$3.3B	$4.2B	$7.5B	$8.7B	$5.2B	$4.9B	$4.7B	-3.6%
Operating Margin	15.8%	14.7%	13.8%	16.4%	16.3%	17.3%	17.1%	17.2%	16.9%	16.3%	16.5%	17.1%	18.3%	19.0%	25.3%	27.6%	21.8%	20.4%	19.1%	-1.3pp
Net Income	$1.4B	$1.3B	$1.2B	$1.8B	$2.2B	$2.4B	$2.7B	$2.6B	$3.4B	$2.6B	$2.5B	$2.7B	$3.0B	$3.6B	$6.4B	$7.2B	$4.8B	$3.9B	$3.6B	-7.3%
Net Margin	12.4%	10.4%	10.3%	13.6%	13.5%	13.1%	14.1%	13.0%	16.3%	15.1%	13.6%	13.3%	16.8%	16.4%	21.8%	22.9%	19.9%	16.3%	14.7%	-1.6pp
Free Cash Flow	$1.5B	$1.7B	$1.6B	$1.9B	$2.3B	$3.0B	$3.0B	$3.2B	$3.2B	$2.9B	$2.9B	$3.4B	$3.3B	$5.4B	$7.1B	$7.4B	$5.8B	$5.3B	$5.3B	-0.7%
FCF Margin	13.5%	13.1%	14.4%	14.1%	14.2%	16.2%	15.9%	15.9%	15.4%	17.4%	15.6%	16.9%	18.5%	24.3%	24.0%	23.4%	24.2%	22.2%	21.4%	-0.8pp
EPS (Diluted)	$4.19	$3.95	$3.46	$2.64	$3.11	$3.36	$3.80	$3.63	$4.74	$3.65	$3.53	$3.74	$4.05	$4.89	$8.61	$9.66	$6.38	$5.29	$5.05	-4.5%

Total Debt$18.4B

Cash & Equiv.$19.9B

Net Cash$1.5B

4 min read

1. THE BIG PICTURE

Danaher is currently a story of operational mastery masking a growth slowdown. While it remains a premier "compounding" engine fueled by its proprietary Danaher Business System (DBS), Danaher Corporation is now navigating a transition where its ability to squeeze 20 cents of free cash flow from every dollar of revenue is more impressive than its ability to find new customers. It is effectively using its best-in-class cash efficiency to fund a buyback program that offsets its status as the slowest-growing firm among its major peers.

2. WHERE THE RISKS HIT HARDEST

The Danaher Business System (DBS), cited as Danaher Corporation's primary engine for "continuous improvement," is being tested by Economic Sensitivity. Management notes that elevated inflation and interest rates are lengthening sales cycles and increasing labor and material costs (10-K Item 1A). This suggests that the "lean" efficiencies of DBS may be reaching a point of diminishing returns if they cannot outpace the structural rise in operating costs, which contributed to a 1.3 percentage point drop in operating margins (XBRL).

Furthermore, the Strategic Capital Allocation priority is threatened by Healthcare Industry Cost Containment. Danaher holds $61.0 billion in goodwill and intangible assets from its acquisition-led growth strategy (10-K Item 1A). If legislative efforts like the Inflation Reduction Act of 2022 successfully reduce reimbursement levels for Danaher’s diagnostics or life sciences products, the projected earnings of these acquired units may fall, forcing a massive non-cash write-down that would erase years of reported book value.

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a stark divergence between top-line momentum and bottom-line efficiency. Danaher ranks last among its peers in revenue growth at +2.9% (TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter), trailing significantly behind leaders like Stryker (+11.2%) and Abbott (+5.7%). However, it leads the entire group in Free Cash Flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin at 20.1% (XBRL). This indicates that while Danaher is struggling to find new volume in a competitive market, it is far more effective than its peers at converting its existing $23.5 billion revenue base into usable cash.

The most recent quarter shows a potential turning point; revenue grew 4.5%, outperforming the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter average of 2.9% (8-K). Management attributes this "strong finish" to "bioprocessing strength" and "improved momentum in Diagnostics" (8-K). This suggests the recent slowdown may be a cyclical trough in the bioprocessing sector rather than a permanent loss of market share, though the 1.6 percentage point compression in net margins indicates that the "momentum" is coming at a higher operational cost. With short interest at a negligible 1.1% of the float, market sentiment remains broadly stable despite these margin pressures (Yahoo Finance).

4. IS IT WORTH IT AT THIS PRICE?

At a Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations of 21.5x, Danaher trades at a 15% premium to the peer median of 18.7x. According to the CAPM analysis, this price implies the market expects 5.1% long-term growth. This expectation is well-aligned with management’s 2026 guidance of 3% to 6% core revenue growth (8-K). The premium is likely justified not by growth—which is currently lagging—but by Danaher’s superior capital return profile; Danaher Corporation leads its peer group with a 2.7% buyback yield (XBRL).

However, the valuation is sensitive to any further deceleration. If growth were to slow to a GDP-pace of 2.5%, the justified multiple would drop to 13.7x, representing a 36% downside from current levels (CAPM analysis). Investors are essentially paying a "quality tax" for the 20.1% FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin, betting that the DBS framework can eventually restore margins to 2024 levels.

5. WHAT WOULD CHANGE THIS VIEW?

Cautious if operating margins continue to compress in 2026 despite the "gradual improvement in end markets" management cited, as this would signal that DBS is no longer sufficient to offset inflationary pressures.
Constructive if core revenue growth exceeds the 6% upper bound of 2026 guidance, particularly if driven by the "bioprocessing" or "SCIEX" product lines mentioned in recent results (8-K).
Cautious if geopolitical tensions lead to a sharp decline in the 11% of sales derived from China, as Danaher Corporation identifies international trade restrictions as a material risk to its current growth strategy (10-K Item 1A).

6. BOTTOM LINE

Structural Advantage: The Danaher Business System (DBS) provides a repeatable framework for high-margin recurring revenue and best-in-class free cash flow conversion. Bottom Line: Danaher is a premium-priced efficiency play that is currently a more compelling story for income-focused investors via buybacks than for those seeking aggressive top-line growth.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Economic Sensitivity: Danaher Corporation is vulnerable to elevated inflation and interest rates, which increase costs for energy, materials, and labor while simultaneously reducing customer capital expenditures and lengthening sales cycles.
Competitive Pricing Pressures: Danaher Corporation operates in intensely competitive industries where it must constantly innovate to avoid commoditization; failure to do so, or the introduction of low-cost private label alternatives by competitors, forces price reductions that compress margins.
Healthcare Industry Cost Containment: Legislative efforts to reduce healthcare costs, such as the Protecting Access to Medicare Act (PAMA) and the Inflation Reduction Act of 2022, threaten the pricing and reimbursement levels for Danaher Corporation’s products.
Acquisition Integration and Strategy: Danaher Corporation’s reliance on acquisitions to drive growth exposes it to risks including the failure to realize anticipated synergies, the assumption of unknown liabilities, and the potential for acquired businesses to underperform relative to the purchase price.
IT and Cybersecurity Vulnerabilities: As a global organization, Danaher Corporation faces risks from cyber-attacks, ransomware, and data breaches that could disrupt operations, result in the theft of intellectual property, and lead to significant regulatory penalties under laws like the GDPR.

2. Company-Specific Risks

Divestiture Contingencies: Danaher Corporation retains responsibility for certain contingent liabilities related to past dispositions (such as Fortive, Envista, and Veralto), which could result in unexpected financial obligations if indemnity rights against new owners prove insufficient.
AI Deployment Risks: Danaher Corporation is in the early stages of incorporating AI into its products and business processes; premature or flawed deployment could lead to competitive harm, loss of intellectual property, or legal liability.
Government Contract Rights: Certain U.S. government agencies have rights to allocate Danaher Corporation’s manufacturing capacity and intellectual property in exchange for financing, which could force Danaher Corporation to prioritize government needs over more profitable commercial contracts.
Clinical Trial Outcomes: Because many products require clinical trials for regulatory clearance, unexpected or unfavorable trial data can lead to the withdrawal of products from the market or the denial of new product approvals.

3. Regulatory/Legal Risks

Data Privacy Compliance: Danaher Corporation is subject to stringent global data privacy laws, including HIPAA and the GDPR; violations can result in fines of up to €20 million or 4% of total worldwide annual turnover.
Tax Audits and Law Changes: Danaher Corporation faces ongoing audits by U.S. and non-U.S. tax authorities; changes in tax laws, such as the OECD’s Pillar Two 15% global minimum tax framework, could retroactively or prospectively increase Danaher Corporation’s effective tax rate.
Trade and Tariff Enforcement: Following the February 2026 U.S. Supreme Court ruling regarding the International Emergency Economic Powers Act, the legal authority for certain tariffs remains uncertain, creating a volatile environment for Danaher Corporation’s supply chain costs and import/export operations.
Off-Label Marketing: Regulatory agencies strictly limit promotional claims to approved intended uses; marketing products for "off-label" use can lead to exclusion from government healthcare programs and significant civil or criminal penalties.

4. Financial Impact Map

Global Economic Conditions → Operating Costs/Revenue → Inflationary pressures on energy, materials, and labor directly impact operating margins and demand for products. Competitive Pricing Pressures → Gross Margin → Pricing competition and the introduction of low-cost alternatives force price reductions, directly impacting the profitability of product sales. Healthcare Cost Containment → Net Sales → Reductions in government funding or reimbursement rates for clinical laboratory testing and medical procedures directly lower the prices customers are willing to pay. Acquisition/Goodwill Impairment → Goodwill and Intangible Assets → With $61.0 billion in carrying value, any failure to integrate acquisitions or meet performance expectations triggers impairment charges that reduce the balance sheet value. Foreign Currency Fluctuations → Financial Statements → Strengthening of the U.S. dollar creates unfavorable translation effects for the 59% of sales derived from outside the U.S. and increases the cost of overseas purchases.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
10-K	Feb 2026	Dec 2025
8-K	Jan 2026	—
10-Q	Oct 2025	Sep 2025
14A	Mar 2025	—